US 12,383,539 B2
Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
Margaret Scott Lee, Middleton, MA (US); Spyridon Papapetropoulos, Wellesley, MA (US); Michelle S. Higgin, Holly Springs, NC (US); Muralikrishna Duvvuri, Chapel Hill, NC (US); Bruce N. Rehlaender, Cary, NC (US); and Evan Newbold, Charlottesville, VA (US)
Assigned to Cavion, Inc., Palo Alto, CA (US)
Appl. No. 17/282,730
Filed by Cavion, Inc., Charlottesville, VA (US)
PCT Filed Oct. 3, 2019, PCT No. PCT/US2019/054498
§ 371(c)(1), (2) Date Apr. 2, 2021,
PCT Pub. No. WO2020/072773, PCT Pub. Date Apr. 9, 2020.
Claims priority of provisional application 62/780,049, filed on Dec. 14, 2018.
Claims priority of provisional application 62/740,755, filed on Oct. 3, 2018.
Prior Publication US 2022/0016095 A1, Jan. 20, 2022
Int. Cl. A61K 31/44 (2006.01); A61K 9/00 (2006.01); A61K 31/4412 (2006.01); A61P 25/08 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01)
CPC A61K 31/4412 (2013.01) [A61K 9/0053 (2013.01); A61K 31/44 (2013.01); A61P 25/08 (2018.01); A61P 25/14 (2018.01); A61P 25/16 (2018.01)] 32 Claims
 
1. An oral dosage form comprising a Cav3 antagonist, wherein the Cav3 antagonist is CX-8998

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein the oral dosage forms comprises a controlled release component comprising said Cav3 antagonist, and wherein the oral dosage form optionally contains an immediate release component comprising said Cav3 antagonist;
wherein said oral dosage form, when administered once daily to a human, is effective to maintain a maximum plasma concentration (Cmax) of said Cav3 antagonist divided by a mean plasma concentration of said Cav3 antagonist at 24 hours after administration

OG Complex Work Unit Math
from about 1.0 to about 4.0.